GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813
Shots:
- Surface Oncology to receive ~$85 M upfront and ~$730 M as milestones along with royalties on net sales of SRF813
- GSK to get an exclusive right to develop and commercialize Surface Oncology’s preclinical program- SRF813
- SRF813 is an IgG1 Ab targeting PVRIG (also k/a CD112)- currently in IND-enabling studies with anticipated IND submission in 2021
Ref: Globe Newswire | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
